Bioprinting, an innovative combination of biotechnology and additive manufacturing, has emerged as a transformative technology in healthcare, enabling the fabrication of functional tissues, organs, and patient-specific implants. The implementation of the aforementioned, however, introduces unique intellectual property (IP) challenges that extend beyond conventional biotechnology. The study explores three critical areas of concern: IP protection for bioprinting hardware and bioinks, ownership and ethical management of digital files derived from biological data, and the implications of commercializing bioprinted tissues and organs. Employing a multidisciplinary approach, the paper analyzes existing IP frameworks, highlights their limitations when applied to bioprinting, and examines ethical dilemmas, such as ownership of bioprinted human tissues and the commodification of biological innovations. Findings suggest that current IP laws inadequately address the complexities of bioprinting, particularly in managing the intersection of proprietary technologies and ethical considerations. The study underscores the need for adaptive legal and ethical frameworks to balance innovation with equitable access and sustainability. Recommendations include the development of tailored IP policies for bioprinting and enhanced international collaboration to harmonize legal protections across jurisdictions. This work aims to provide a comprehensive foundation for stakeholders to navigate the rapidly evolving landscape of bioprinting IP.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3390/bioengineering12010076 | DOI Listing |
Nat Med
January 2025
Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), University of Vic - Central University of Catalonia, Barcelona, Spain.
Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with chemotherapy regimens has had limited efficacy. The phase 3 BREAKWATER study investigated EC+mFOLFOX6 versus standard of care (SOC) in patients with previously untreated BRAF V600E mCRC.
View Article and Find Full Text PDFNat Commun
January 2025
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Gut microbiota disruptions after allogeneic hematopoietic cell transplantation (alloHCT) are associated with increased risk of acute graft-versus-host disease (aGVHD). We designed a randomized, double-blind placebo-controlled trial to test whether healthy-donor fecal microbiota transplantation (FMT) early after alloHCT reduces the incidence of severe aGVHD. Here, we report the results from the single-arm run-in phase which identified the best of 3 stool donors for the randomized phase.
View Article and Find Full Text PDFInt J Med Inform
January 2025
Oulu Advanced Research on Service and Information Systems, University of Oulu, Linnanmaa campus, Pentti Kaiteran katu 1 90570 Oulu, Finland. Electronic address:
Background: Studies have demonstrated that interventions targeting weight loss and body mass index (BMI) reduction can be successful, although the specific factors that influence their effectiveness are still unclear. Behavior change support systems (BCSS) are an approach that aims to help users in their efforts to modify their behavior. A useful tool for assessing BCSS is the Persuasive Systems Design model (PSD), where different features and postulates can be employed.
View Article and Find Full Text PDFPolymers (Basel)
January 2025
Department of Mechanical Engineering, Debre Markos University, Debre Markos 251, Ethiopia.
In the rapidly evolving biobased materials innovation landscape, our research identifies key players and explores the evolutionary perspective of biobased innovation, offering insights into promising research areas to be further developed by biobased material scientists in search of exploiting their knowledge in novel applications. Despite the crucial role of these materials in promoting sustainable production and consumption models, systematic studies on the current innovation terrain are lacking, leaving gaps in understanding key players, emerging technologies, and market trends. To address this void, we focused on examining patents related to biobased monomers and polymers, aiming to describe the innovation strategies and business dynamics of leading assignees.
View Article and Find Full Text PDFVet Parasitol Reg Stud Reports
January 2025
Southeastern Cooperative Wildlife Disease Study, Department of Population Health, College of Veterinary Medicine, Wildlife Health Building, 589 D.W. Brooks Dr., University of Georgia, Athens, GA 30602, USA; Warnell School of Forestry and Natural Resources, University of Georgia, Athens, GA 30602, USA; Center for Ecology of Infectious Diseases, University of Georgia, Athens, GA 30602, USA. Electronic address:
Ticks are medically important vectors of pathogens, many of which are zoonotic or impact domestic animal and/or wildlife health. Climate change, landuse modifications, and increasing interactions between domestic animals, wildlife, and humans have resulted in changes in tick-host dynamics and the emergence of novel pathogens worldwide. Therefore, describing the host and geographic ranges of vector species is essential in assessing disease risk, especially in understudied areas, and should be conducted in a One Health context.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!